Skip to main content

Table 2 Included studies with their major findings

From: Efficacy and safety of azithromycin and amoxicillin/clavulanate for otitis media in children: a systematic review and meta-analysis of randomized controlled trials

Author (year) Target population age range (Children) Study place Sample size Clinical success %Azithromycin/amoxicillin-clavulanate P-value (95% CI)
Daniel (1993) (2–8 year) with OM Europe Multi center 159 99%/100% NS (N/A)
Schaad (1993) 6 months to 12 years with AOM Switzerland 389 93.2%/97.4% NS (N/A)
Principi (1995) (6-months to 12 years) with OM Brazil, Chile, Germany, Italy, Korea, Spain, Turkey Venezuela 483 92.6%/93.9%) NS (N/A)
Arguedasa et al. (1996) 6-months to 12 years with OM with effusion San Jose Costa Rica 100 82.5%/78.9%) NS (N/A)
Gerson (1996) 2 to 15 years with Acute otitis media USA 169 87.7%/100% 0.102 (N/A)
Mohini (1996) (6-months to 12 years) with Acute otitis media USA 527 92.3%/90% 0.417 (N/A)
Samuel (1996) 1 to 15 years with AOM USA 677 87.6%/87.9% 0.636 (N/A)
Dagan (2000) 6 months to 2 years with AOM Israel USA and Dominican Republic 238 70% / 85.7% 0.023 (2,30)
Arrieta et al. (2003) 6-months to 6 years with recurrent or persistent AOM USA, Latin American centers 304 85.9%/84.1%) 0.744 (− 6.4, 10)
Block et al. (2003) (6-months to 12 years) with AOM USA 350 86.9%/87.7% NS (− 9.2, 6.5)
Dune et al. (2003) (6-months to 12 years) with AOM USA 373 82.7%/88.3% 0.186 (− 13, 3)
Hoberman et al. (2005) 6 month to 30 month with AOM USA. Bulgaria, Chile, Domenica Republic, Guatemala, Israel, Peru, Romania Latvia Mexico, 731 80.9%/90.5%  < 0.01 (2.37,17)
Guven et al. (2006) (6-months to 12 years) with AOM Turkey 180 100%/100% 0.24 (N/A)
Arguedas et al (2011) 3 months–4 years with AOM North America, Europe, and Latin America 923 80.2%/84.5% 0.24 (− 10.4, 2.6)
  1. NS, non-significant; N/A, not-available; AOM, acute otitis media; OM, otitis media